Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElementis Regulatory News (ELM)

Share Price Information for Elementis (ELM)

Share Price is delayed by 15 minutes
Get Live Data
156.40    3.60 (2.36%)
Bid:
156.20
Ask:
156.60
Spread: 0.40 (0.256%)
Market Cap: £895.10m
ELM Live PriceLast checked at - London Stock Exchange

Intraday Elementis Share Chart

AGM / Interim Management Statement

27 Apr 2016 07:00

ELEMENTIS PLC - AGM / Interim Management Statement

ELEMENTIS PLC - AGM / Interim Management Statement

PR Newswire

London, April 26

27 April 2016

AGM / Interim Management Statement

Elementis plc (ELM.L, the “Company" or the “Group"), the Global Specialty Chemicals Company, today issues its Interim Management Statement for the three months ended 31 March 2016.

Commenting on the Company’s performance Group Chief Executive, Paul Waterman, said: “During my first two months at Elementis I have been impressed by the quality of our people and the resilience of our business model. This is best exemplified by the sustained level of contribution margins in Specialty Products, the relative stability of the Chromium business in North America and the Group’s strong cash generation. Although some markets continue to be challenging and we are cycling against a stronger first quarter in 2015, we are proactively managing our margins and cost base to ensure that our performance for the year remains in line with management expectations.”

In Specialty Products, sales performance in coatings and personal care was satisfactory, while currency and lower oilfield sales resulted in total sales being 7 per cent below the same period last year. The following comments by division refer to constant currency sales:

In coatings additives, sales in North America were similar to the previous year as sales of decorative products from the New Martinsville plant continued to make good progress, while industrial sales remained subdued due to the impact of the stronger dollar on consumer exports, as previously reported. Sales in Europe were 1 per cent higher, while sales in Asia Pacific were 1 per cent lower, following the destocking and adjustment that took place in the Chinese economy in the second quarter of 2015. Sales to Latin America represent 5 per cent of total coatings sales and were 9 per cent lower than the previous year due to economic weakness in that region, particularly in Brazil.

In personal care, sales were 4 per cent higher than the previous period, as the business continued to benefit from geographic expansion and new product sales.

Sales in oilfield drilling were broadly in line with the quarterly sales run rate experienced in the second half of 2015, following the sharp downturn in North American demand that took place in the early part of 2015. Consequently, sales for the current quarter were 37 per cent below the same quarter last year.

As anticipated, Chromium sales for the first quarter were 11 per cent lower than the previous year, as market conditions outside of North America continued to be challenging. Although sales in North America were lower by 5 per cent, this is largely due to order timing and sales for the first six months of the year are expected to be in line with the same period last year. Sales outside of North America were 19 per cent lower than the previous year, with volumes lower by 6 per cent and pricing lower by 13 per cent.

The Group’s balance sheet remains strong and is again expected to be in a net cash position at the end of the year which, under our dividend policy, will continue to provide shareholders with attractive returns.

ENDS

Enquiries:

Elementis Paul Waterman, Chief Executive Brian Taylorson, Finance Director+ 44 (0) 207 067 2999
FTI Consulting Deborah Scott Matthew Cole+ 44 (0) 203 727 1000
Date   Source Headline
16th Jan 20251:45 pmRNSHolding(s) in Company
2nd Jan 202510:06 amRNSTotal Voting Rights
24th Dec 20247:00 amRNSDirectorate Change
9th Dec 20245:05 pmRNSDirector/PDMR Shareholding
2nd Dec 202410:06 amRNSTotal Voting Rights
18th Nov 20247:00 amRNSChief Executive Succession
1st Nov 20249:54 amRNSTotal Voting Rights
29th Oct 20247:00 amRNSThird Quarter Trading Update
11th Oct 202411:18 amRNSDirector/PDMR Shareholding
17th Sep 20248:50 amRNSDirector/PDMR Shareholding
2nd Sep 20249:31 amRNSBlock listing Interim Review
23rd Aug 202410:31 amRNSHolding(s) in Company
14th Aug 202410:53 amRNSAdditional Listing
9th Aug 20242:43 pmRNSHolding(s) in Company
2nd Aug 20245:44 pmRNSHolding(s) in Company
1st Aug 20243:10 pmRNSCorrection of dividend record date
1st Aug 20247:00 amRNSHalf-year Report
15th Jul 202410:59 amRNSHolding(s) in Company
30th May 202412:52 pmRNSDirector/PDMR Shareholding
29th May 20241:07 pmRNSDirector Declaration
8th May 202411:08 amRNSDirector/PDMR Shareholding
3rd May 202411:46 amRNSHolding(s) in Company
1st May 202410:06 amRNSTotal Voting Rights
30th Apr 202411:36 amRNSResult of AGM
30th Apr 20247:00 amRNSFirst quarter trading update
29th Apr 202412:13 pmRNSResponse to open letter from Gatemore
12th Apr 202411:33 amRNSDirector/PDMR Shareholding
12th Apr 202411:28 amRNSDirector/PDMR Shareholding
9th Apr 20246:04 pmRNSDirector/PDMR Shareholding
26th Mar 20244:07 pmRNSAnnual Financial Report & Notice of AGM
19th Mar 20243:02 pmRNSAdditional Listing
15th Mar 20241:00 pmRNSDirectorate Change
12th Mar 20244:38 pmRNSDirector/PDMR Shareholding
12th Mar 20244:33 pmRNSDirector/PDMR Shareholding
8th Mar 20245:56 pmRNSDirector/PDMR Shareholding
7th Mar 20247:00 amRNSDirectorate changes
7th Mar 20247:00 amRNSPreliminary results year ended 31 December 2023
1st Mar 20249:30 amRNSBlock listing Interim Review
18th Jan 20247:00 amRNSTrading Update
2nd Jan 20249:45 amRNSTotal Voting Rights
1st Dec 202310:46 amRNSTotal Voting Rights
30th Nov 20239:38 amRNSDirector/PDMR Shareholding
14th Nov 20237:00 amRNS2023 Capital Markets Day
1st Nov 20239:46 amRNSTotal Voting Rights
31st Oct 20237:00 amRNSThird Quarter Trading Update
2nd Oct 20239:34 amRNSTotal Voting Rights
20th Sep 202312:09 pmRNSResponse to open letter from Franklin Templeton
12th Sep 20233:13 pmRNSDirector Declaration
8th Sep 20239:30 amRNSHolding(s) in Company
1st Sep 20239:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.